CXCL10 and inflammatory response: The anti‐inflammatory effects of baricitinib have also been demonstrated by the reduction in serum levels of IFN‐γ, IP‐10, GM‐CSF, and MCP‐1 in pediatric patients with steroid‐dependent chronic inflammation, resulting in control of disease activity and the ability to wean or taper steroids (Sanchez et al, 2018).